2121非凡体育官方网站

2024-06-26 Grand Pharma at the Respiratory Event: Sharing Cutting-Edge Theories and Clinical Applications in Respiratory Medicine

2024-06-26 Grand Pharma Appears at the 88th PHARMCHINA

2024-06-11 The Phase I Clinical Study Conducted in China of the Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment

2024-05-31 Grand Pharma 2024 Investor Open Day

2024-04-24 Employer Presentations at Wuhan University and Huazhong University of Science and Technology

2024-03-28 Grand Pharma Introduces a Global Innovative Product for the Treatment of Demodex Blepharitis and Meibomian Gland Disease with Demodex Mites

2024-03-25 The Global Innovative RDC Drug of Grand Pharma ITM-11 Is Approved to Conduct Phase III Clinical Study in China

2024-03-22 Grand Pharma Announced Annual Results for the Year Ended 31 December 2023

2024-03-11 Grand Pharma’s Two Global Innovative Ophthalmic Products Have Achieved Significant Progress. The NDA of GPN00833 Has Been Approved by the FDA, GPN00884 Has Been Approved to Conduct Phase I Clinical Study in China

2024-01-26 Grand Pharma’s Milestone in the Layout of Structural Heart Field, the Establishment of Shanghai R&D Center

2024-01-26 The IND Application in China of Grand Pharma’s Global Innovative Therapeutic Tumor Vaccine ARC01 Was Approved

2024-01-24 Grand Pharma Strategically Controls Duoputai Pharmaceutical Technology, Strengthening the Strategic Plan in Field of Cerebro-cardiovascular Disease Treatment